The Pharmaceutical Index: 2013 Worldwide NCEs
Editat de Ltd. Pharmacodia (Beijing) Co.en Limba Engleză Hardback – 28 noi 2016
Preț: 2617.98 lei
Preț vechi: 3696.46 lei
-29%
Puncte Express: 3927
Preț estimativ în valută:
462.81€ • 551.81$ • 401.42£
462.81€ • 551.81$ • 401.42£
Carte indisponibilă temporar
Doresc să fiu notificat când acest titlu va fi disponibil:
Se trimite...
Specificații
ISBN-13: 9787506778787
ISBN-10: 7506778785
Pagini: 546
Dimensiuni: 203 x 297 mm
Greutate: 2.02 kg
Ediția:1
Editura: CRC Press
Colecția CRC Press
Locul publicării:Boca Raton, United States
ISBN-10: 7506778785
Pagini: 546
Dimensiuni: 203 x 297 mm
Greutate: 2.02 kg
Ediția:1
Editura: CRC Press
Colecția CRC Press
Locul publicării:Boca Raton, United States
Public țintă
Academic and Professional Practice & DevelopmentCuprins
Executive Summary
Chapter 1: Acotiamide Hydrochloride Hydrate
Chapter 2: Afatinib Dimaleate
Chapter 3: Canagliflozin Hemihydrate
Chapter 4: Cetilistat
Chapter 5: Cobicistat
Chapter 6: Dabrafenib Mesylate.
Chapter 7: Dimethyl Fumarate
Chapter 8: Dolutegravir Sodium
Chapter 9: Efinaconazole
Chapter 10: Elvitegravir
Chapter 11: Glycerol Phenylbutyrate
Chapter 12: Ibrutinib
Chapter 13: Istradefylline
Chapter 14: Levomilnacipran Hydrochloride
Chapter 15: Macitentan
Chapter 16: Olodaterol Hydrochloride
Chapter 17: Ospemifene
Chapter 18: Pomalidomide
Chapter 19: Riociguat
Chapter 20: Simeprevir Sodium
Chapter 21: Sofosbuvir
Chapter 22: Topiroxostat
Chapter 23: Trametinib Dimethyl Sulfoxide
Chapter 24: Vortioxetine Hydrobromide
Appendix I. Abbreviation
Appendix II. Worldwide Approved NCEs (2001-2014)
Chapter 1: Acotiamide Hydrochloride Hydrate
Chapter 2: Afatinib Dimaleate
Chapter 3: Canagliflozin Hemihydrate
Chapter 4: Cetilistat
Chapter 5: Cobicistat
Chapter 6: Dabrafenib Mesylate.
Chapter 7: Dimethyl Fumarate
Chapter 8: Dolutegravir Sodium
Chapter 9: Efinaconazole
Chapter 10: Elvitegravir
Chapter 11: Glycerol Phenylbutyrate
Chapter 12: Ibrutinib
Chapter 13: Istradefylline
Chapter 14: Levomilnacipran Hydrochloride
Chapter 15: Macitentan
Chapter 16: Olodaterol Hydrochloride
Chapter 17: Ospemifene
Chapter 18: Pomalidomide
Chapter 19: Riociguat
Chapter 20: Simeprevir Sodium
Chapter 21: Sofosbuvir
Chapter 22: Topiroxostat
Chapter 23: Trametinib Dimethyl Sulfoxide
Chapter 24: Vortioxetine Hydrobromide
Appendix I. Abbreviation
Appendix II. Worldwide Approved NCEs (2001-2014)
Recenzii
‘This new series of Pharmaceutical Indexes will be a boon in academia and the pharmaceutical industry, and provide, as well, a significant addition to the therapeutics discovery arsenal. It should also find a wide audience in government, and the business community.’
– K. Barry Sharpless, Nobel Prize Winner in Chemistry, 2001.
‘The most fruitful basis for the discovery of a new drug is to start with an old drug.’
– James W. Black, Nobel Prize Winner in Physiology or Medicine, 1998.
– K. Barry Sharpless, Nobel Prize Winner in Chemistry, 2001.
‘The most fruitful basis for the discovery of a new drug is to start with an old drug.’
– James W. Black, Nobel Prize Winner in Physiology or Medicine, 1998.
Descriere
An ideal drug candidate should possess good pharmacological activity, absorption, distribution, metabolism, excretion and toxicity properties. Historically, there are around 6,000 drugs being used in humans and approximately 3,000 still in clinical use, not including herbal medicines. This Pharmaceutical Index series focuses on the profiles of 500 pharmaceutically marketed products from the past two decades. Professor Dr. K. Barry Sharpless is Honorary Editor-in-Chief of this first Index by Pharmacodia. The volume includes 24 NCEs worldwide approved drugs in 2013. Pharmacodia plan to publish two further volumes which will feature 2014 NCEs (32 drugs) and 2015 NCEs (25 drugs).